Rubin J, Kvols L K, Moertel C G, Jones A R, Hahn R G, O'Connell M J
Am J Clin Oncol. 1983 Aug;6(4):477-9. doi: 10.1097/00000421-198308000-00015.
A phase II study of ADAH was conducted in thirty patients with biopsy-prove metastatic or recurrent colorectal carcinoma in order to define its benefits and toxicity. Doses were adjusted by leukocyte nadirs. No patients met the criteria for complete or partial response.
对30例经活检证实为转移性或复发性结肠直肠癌患者进行了一项ADAH的II期研究,以确定其疗效和毒性。根据白细胞最低点调整剂量。没有患者达到完全缓解或部分缓解的标准。